局部晚期食管癌新辅助放化疗后应用18F-FDG PET/CT检测间期远处转移
本回顾性研究纳入2017至2021年127例接受新辅助放化疗及手术计划的局部晚期食管癌患者,评估现有预测模型的外部效能。17例(13%)发生间期远处转移,9例(7%)为PET/CT假阳性。现有模型区分度c-statistic为0.56,校准不佳,无法可靠识别高风险患者;临床II期患者间期远处转移发生率5%。
要点
- 127例局部晚期食管癌患者中17例(13%)发生间期远处转移,9例(7%)PET/CT假阳性。
- 现有预测模型外部区分度c-statistic为0.56(95%CI 0.40-0.72),校准不佳,低估实际风险。
- 临床II期间期远处转移真阳性率5%、假阳性率0%,作者认为可考虑省略新辅助放化疗后PET/CT再分期。
核心结论
- 现有预测模型无法可靠识别食管癌新辅助放化疗后发生间期远处转移的风险患者。
- 作者认为,临床II期食管癌患者可考虑省略新辅助放化疗后的18F-FDG PET/CT再分期。
研究设计与样本
- 回顾性研究,纳入2017至2021年接受基线及再分期18F-FDG PET/CT、新辅助放化疗并计划行食管切除术的局部晚期食管癌患者127例。
- 主要结局为现有预测模型预测间期远处转移的外部效能(区分度与校准度),模型预测因子包括肿瘤长度、cN状态、鳞状细胞癌组织学及基线SUVmax。
- 次要结局为确定腺癌和鳞状细胞癌中间期远处转移发生率<10%的临床分期组(AJCC/UICC第八版)。
主要发现
- 127例中17例发生间期远处转移(13%;95%CI 8%-21%),9例18F-FDG PET/CT病灶判定为假阳性(7%;95%CI 2%-11%)。
- 现有模型应用于本队列的区分度c-statistic为0.56(95%CI 0.40-0.72),校准度差,主要低估实际风险。
- 临床II期患者间期远处转移真阳性率5% vs 假阳性率0%;临床III期真阳性率14% vs 假阳性率8%;临床IVa期真阳性率22% vs 假阳性率9%。
关键数值与推荐
- 现有预测模型预测间期远处转移的c-statistic为0.56(95%CI 0.40-0.72)。
- 临床II期间期远处转移真阳性率5%、假阳性率0%;临床III期真阳性率14%、假阳性率8%;临床IVa期真阳性率22%、假阳性率9%。
临床怎么用
- 作者认为,临床II期食管癌患者可考虑省略新辅助放化疗后的18F-FDG PET/CT再分期。
- 现有预测模型不能可靠识别间期远处转移风险患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with esophageal cancer can develop distant metastases between the start of neoadjuvant chemoradiotherapy (nCRT) and planned surgery (ie, interval distant metastases). 18F-FDG PET/CT restaging after nCRT detects interval distant metastases in ~8% of patients. This study aimed to identify patients for whom 18F-FDG PET/CT restaging after nCRT could be omitted using an existing prediction model predicting for interval distant metastases or by using clinical stage groups. PATIENTS AND METHODS: Patients with locally advanced esophageal cancer who underwent baseline and restaging 18F-FDG PET/CT, nCRT, and were planned for esophagectomy between 2017 and 2021 were eligible for inclusion in this retrospective study. The primary outcome was the existing model's external performance (ie, discrimination and calibration) for predicting interval distant metastases. The existing model predictors included tumor length, cN status, squamous cell carcinoma histology, and baseline SUVmax. The secondary outcome determined the clinical stage groups (AJCC/UICC eighth edition) for adenocarcinoma and squamous cell carcinoma for which the incidence of interval distant metastases was <10%. RESULTS: In total, 127 patients were included, of whom 17 patients developed interval distant metastases (13%; 95% confidence interval [CI], 8%-21%) and 9 patients were deemed to have false-positive lesions on 18F-FDG PET/CT (7%; 95% CI, 2%-11%). Applying the existing model to this cohort yielded a discriminatory c-statistic of 0.56 (95% CI, 0.40-0.72). The calibration of the existing model was poor (ie, mostly underestimating the actual risk). The incidence of true-positive versus false-positive interval distant metastases for patients with clinical stage II disease was 5% versus 0%; clinical stage III, 14% versus 8%; and clinical stage IVa, 22% versus 9%. CONCLUSIONS: The existing prediction model cannot reliably identify patients at risk for developing interval distant metastases after nCRT for esophageal cancer. Omission of 18F-FDG PET/CT restaging after nCRT could be considered in patients with clinical stage II esophageal cancer.
引用
- Kroese TE, Ruurda JP, Bakker AS, et al. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer. Clin Nucl Med. 2022. PMID: 35384907. doi:10.1097/RLU.0000000000004191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。